864 related articles for article (PubMed ID: 32655582)
1. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment.
Bertoni A; Penco F; Mollica H; Bocca P; Prigione I; Corcione A; Cangelosi D; Schena F; Del Zotto G; Amaro A; Paladino N; Pontali E; Feasi M; Signa S; Bustaffa M; Caorsi R; Palmeri S; Contini P; De Palma R; Pfeffer U; Uva P; Rubartelli A; Gattorno M; Volpi S
J Allergy Clin Immunol; 2022 Oct; 150(4):796-805. PubMed ID: 35835255
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
7. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
Zhao N; Di B; Xu LL
Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
[TBL] [Abstract][Full Text] [Related]
8. Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19.
Manayi A; Nabavi SM; Khayatkashani M; Habtemariam S; Khayat Kashani HR
Mol Biol Rep; 2021 Dec; 48(12):8221-8225. PubMed ID: 34655016
[TBL] [Abstract][Full Text] [Related]
9. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
10. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome.
Sano S; Oshima K; Wang Y; MacLauchlan S; Katanasaka Y; Sano M; Zuriaga MA; Yoshiyama M; Goukassian D; Cooper MA; Fuster JJ; Walsh K
J Am Coll Cardiol; 2018 Feb; 71(8):875-886. PubMed ID: 29471939
[TBL] [Abstract][Full Text] [Related]
11. The Nlrp3 Inflammasome Orchestrates Mobilization of Bone Marrow-Residing Stem Cells into Peripheral Blood.
Lenkiewicz AM; Adamiak M; Thapa A; Bujko K; Pedziwiatr D; Abdel-Latif AK; Kucia M; Ratajczak J; Ratajczak MZ
Stem Cell Rev Rep; 2019 Jun; 15(3):391-403. PubMed ID: 31089880
[TBL] [Abstract][Full Text] [Related]
12. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
Quagliariello V; Bonelli A; Caronna A; Lombari MC; Conforti G; Libutti M; Iaffaioli RV; Berretta M; Botti G; Maurea N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9169-9171. PubMed ID: 32965010
[TBL] [Abstract][Full Text] [Related]
14. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
Agarwal S; Pethani JP; Shah HA; Vyas V; Sasane S; Bhavsar H; Bandyopadhyay D; Giri P; Viswanathan K; Jain MR; Sharma R
Bioorg Med Chem Lett; 2020 Nov; 30(21):127571. PubMed ID: 32980515
[TBL] [Abstract][Full Text] [Related]
16. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
17. Inflammasome formation in the lungs of patients with fatal COVID-19.
Toldo S; Bussani R; Nuzzi V; Bonaventura A; Mauro AG; Cannatà A; Pillappa R; Sinagra G; Nana-Sinkam P; Sime P; Abbate A
Inflamm Res; 2021 Jan; 70(1):7-10. PubMed ID: 33079210
[TBL] [Abstract][Full Text] [Related]
18. The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury.
Irrera N; Russo M; Pallio G; Bitto A; Mannino F; Minutoli L; Altavilla D; Squadrito F
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867310
[TBL] [Abstract][Full Text] [Related]
19. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
